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Thrombin is the enzyme of the haemostasis system that stands at the crossroads between the 
coagulation cascade and coagulation inhibition by protein C, between plasma coagulation factors 
and cells involved in haemostasis and between haemostasis and the immune system. Allosteric 
regulation of thrombin and its interaction with various partners in blood plasma and on the surface of 
the endothelium and platelets provides a wide variety of thrombin functions. The thrombin activity 
regulation is multifactorial, so a failure of any part of this system leads to serious consequences. An 
example of this are thrombotic/bleeding complications during endothelial dysfunction, infections, 
inflammation and uncontrolled treatment. 
This review aims to summarize current knowledge about thrombin structure, functions and 
regulation. Collected data suggest a crucial role of thrombin in different pathologies accompanied 
by blood coagulation disorders, in particular diseases causing endothelial dysfunction, such as 
COVID-19. 
(Korolova D. Regulation and Dysregulation of Thrombin Activity. SEEMEDJ 2021; 5(1); 47-64) 
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Platelet haemostasis and blood coagulation 
have important and strong interactions, such as 
positive and negative feedback loops and 
surface-bound enzyme complexes formation. 
Thrombin is the resulting enzyme produced by 
the coagulation cascade. It provides not only 
clot formation, but also a strong enzymatic 
feedback activity in procoagulant and 
anticoagulant reactions and platelet reactivity 
(1).  
The main thrombin functions are: 1) turning 
soluble fibrinogen to fibrin, that is forming the 
protein-polymer core of the thrombus; 2) 
activating platelets; 3) activating clotting factors 
V, VII, VIII and XI, which enhance thrombin 
formation; and 4) limiting its own production by 
binding thrombomodulin and converting protein 
C (PC) to activated protein C, which 
subsequently inhibits clotting factors Va and 
VIIIa. 
Thrombin functions extend beyond blood 
coagulation and include vascular functioning (2) 
and in particular, thrombin regulates 
inflammation and regeneration (3). Through 
PAR-receptors, it stimulates monocytes, T 
lymphocytes, leukocytes, endothelial cells, 
fibroblasts, tissue macrophages, neutrophils and 
mast cells (4-6). This way, thrombin mediates the 
crosstalk between the coagulation system and 
the adaptive immune system at the sites of 
vascular injury (6). Thrombin also enhances 
proliferation of endothelial cells, epithelium, 
fibroblasts, smooth muscle and neuromuscular 
cells and provides an antiviral response (4-6); 
participates in the development of malignant 
tumours (stimulates the adhesive and metastatic 
capacity of tumour cells and activates 
angiogenesis in the tumour area); regulates the 
development and apoptosis of nerve cells and 
neuralgia in the embryonic period and after birth; 
and controls the survival of the myoblast, the 
development of the placenta and the embryo as 
a whole (2-4, 7, 8).  
Thrombin is acknowledged as the central 
enzyme of haemostasis because of the 
numerous and multi-directional functions it 
possesses. When it is present in the 
bloodstream in pathological conditions, it 
directly triggers intravascular thrombosis and is 
a marker thereof at the same time. This is why 
understanding molecular mechanisms of 
thrombin regulation is important for both 
laboratory diagnostics and correction of 
imbalance in the haemostasis system. Thus, the 
situation with thrombin studies and application is 
a bit of a paradox. Generation of active thrombin 
is the main factor of intravascular clotting. 
However, tests indicating thrombin activity or 
detecting prothrombin activation products are 
not used as routine laboratory diagnostic tests. 
Also, thrombin is the main target of 
anticoagulant therapy and at the same time, it 
can provide both pro-coagulant and 
anticoagulant action. Only a few research 
groups are working to find ways to switch 
thrombin activity and direct it to the 
anticoagulant pathway. This is a promising 
direction in the search for a fundamentally new 
treatment of haemostasis disorders. 
This article is focused on summarizing current 
knowledge about the diversification of thrombin 
functions and substrates selection for the 
purpose of drawing the attention of medical 
professionals to the importance of using 
thrombin-specific tests in routine laboratory 
diagnostics both with regard to haemostasis 
disorders and infectious diseases.  
Thrombin sites  
Thrombin is a multifunctional serine protease of 
the haemostasis system. It cleaves more than 10 
substrates, but remains highly specific to each 
one of them. Functional plasticity of thrombin is 
associated with the presence of effector sites 
(exosites I and II), which together with the active 
site are involved in the recognition and binding 
of the substrate; action directionality modulated 
by Na+ coordination; and significant 
conformational mobility and plasticity of the 
molecule (9, 10). In addition, it should be noted 
that the multi-directionality of thrombin is 
ensured by its interaction with different partners, 
so thrombin is characterized by homotropic 
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allosteric regulation. In this context, two 
populations of thrombin can be determined: free 
and membrane-bound. 
The thrombin active site is typical for enzymes of 
the chymotrypsin family of serine proteases. 
Thrombin substrates have a positively charged 
amino acid (usually arginine) on the N-terminus 
in the cleavage bond (11) (Figure 1).  
 
Figure 1. Thrombin substrate recognition 
scheme (based on [11, 12]). 
HPh - hydrophobic amino acid residue 
”– Pro or monoamine monocarbon amino acid residue 
* - only for heparin cofactor II this position is occupied 
by Leu 
© Korolova, 2021 
 
The active site cleft is formed by two loops 
around the active site, which are longer than 
such loops in chymotrypsin (12). The 60-loop is 
hydrophobic and rigid. It forms a cap over an 
active site and provides interaction with N-
terminal hydrophobic substrate residues. The γ
‐loop is more hydrophilic and flexible in nature. It 
is adjacent to the active site cleft of thrombin, it 
can contact substrate residues C‐terminal to the 
scissile bond and can make contacts with the 
body of the substrate protein. Conformational 
changes in the thrombin molecule and changes 
in its catalytic activity result in the binding of 
exosites I and II of thrombin to the ligands (Table 
1). This is confirmed by a functional analysis that 
demonstrates the relationship between the 
exosites and the position of the γ-loop of the 
catalytic centre. The γ-loop can block access to 
the “gap" of the active site. Active site 
environments for the individual binary 
complexes or the ternary thrombin complex are 
different, such that each binary and ternary 
thrombin complex could be expected to display 
unique catalytic properties. At the same time, 
there is no linkage between exosites I and II 
structures. Exosite I is formed by Lys36, His71, 
Arg73, Arg75, Tyr76, Arg77, Lys109 and Lys110; 
exosite II by Arg93, Lys236, Lys240, Arg101 and 
Arg233 (11). Exosite I interacts with the C-
terminus of the substrate, and exosite II with the 
N-terminus of the substrate or cofactor 
It is suggested that the interaction of ligands with 
the exosites of thrombin results in the 
displacement of ions from the exosites. In 
particular, it is known that the efficiency of 
interaction with exosite II is strongly dependent 
on the concentration of NaCl, in contrast to the 
interaction with exosite I (13, 14). Both exosites 
require peptides with a high percentage of 
acidic residues, 50 % for exosite I and 72 % for 
exosite II, but the hydrophobic content is lower 
for exosite II. J. Huntington (11) analyzed how 
thrombin chooses to bind ligands to exosite I or 
II. The main difference between the exosites is 
the ratio of negatively charged and hydrophobic 
amino acids. All exosite I-interacting peptides 
have a ratio below two and all exosite II-
interacting peptides have a ratio above two. 
Therefore, exosite II is the only true anion-
binding site of thrombin and exosite I is actually 
the “apolar-binding exosite”.  
Thrombin can interact with ligands by active site 
only (low-weight substrate), by active site and 
one of the exosites or by active site and both 
exosites (thrombomodulin binds simultaneously 
to thrombin exosite I through its growth factor 
domains and to exosite II through a chondroitin 
sulphate moiety). Such interaction variability 
provides specific recognition of a large range of 
substrates and their unique rearrangements 
provide thrombin enzymatic specificity due to 
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such recognition. The role of exosites in 
substrate recognition may not be equal. In 
particular, fibrinogen recognition is dominated 
by exosite I binding and exosite II plays a 
secondary role in this process. Eventually, 
fibrinogen successfully binds to exosite I of 
active-site-blocked thrombin (15).  
Table 1. Thrombin ligands and characteristics of interaction 
Ligand  
Bound site  Kinetic parameters without 
Cofactor 
Cofactor  




exosite I Kd= 0.52 *10-6M  
(higher affinity site)  
Kd= 180*10 -6M  







kd= 7*10-6 M 
kcat/Km = 13.9 *106M-1s-1 
(for FpA release) 
kcat/Km = 4.0 *106M-1s-1 













Km = 12.6 *10-9M - - 
factor ХІІІ  
[59] 
active site 
kcat/Km = 1.4*105M-1s-1 
Fibrin 
(in exosite I) 




Kd = 5*10-7-10-8 M - 
- 
PAR-1 [91, 92] 
exosite I 
active site 
kcat/Km = 3*106M-1s-1 
GРIb  
 




active site kcat/Km = 5.6*102 M–1s–1 ТМ 
(in exosite I, 
exosite II) 
kcat/Km = 5.9*106 M–1s–1 
TAFI  
[94, 95] 
active site kcat/Km = 0.96*103 M-1s-1 ТМ 
(in exosite I, 
exosite II) 
kcat/Km = 1.2*106 M-1s-1 






Kd = 1 - 4.9 * 10-9M 
 - - 
Antithrombin ІІІ 
[97] 
active site kcat/Km = 6.8*103 M-1s-1 
heparin 
kcat/Km = 1.2*108 M-1s-1 
Heparin 







Kd = 4*10-8M 
(heparin) 




exosite II Kd = 1.1*10-7M 
(low molecular weight) 
Kd =0.9 10-7M 




exosite II Kd = 3.6*10-6M 
- - 
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An interesting example of the regulation 
significance of thrombin interaction by exosites 
is fibrinogen γ’ binding. Fibrinogen γ’ is a 
product of alternative splicing. It has an 
alternative chain with the final four C-terminal 
residues replaced with 20 different residues, 
with a high proportion of negatively charged 
residues. Fibrinogen γ’ has an average plasma 
concentration from 8 % to 15 %. [16]. Fibrinogen 
γ’ chain carboxyl terminus strongly binds to 
thrombin exosite II (16). As a result, fibrinogen γ
’ reduces thrombin inhibition by antithrombin III 
(AT III) and heparin cofactor ІІ (HC II) and 
competes for binding to thrombin with factor VIII. 
On the other hand, binding to γ’ fibrinogen 
reduces thrombin blood circulation. In addition, 
fibrinogen γ’ forms fibrin clots that are 
resistant to fibrinolysis. So, even a change in the 
strength of thrombin exosite II binding to 
fibrinogen translates into a dramatically different 
way of clot formation, its content, density and 
strength of the fibrin network.  
It should be noted that there is a competition 
between cofactors for thrombin exosites 
binding, which has a significant effect on 
thrombin’s enzymatic orientation. 
Thrombomodulin (TM) and fibrin have been 
shown to compete for exosite I thrombin 
binding. However, thrombin has a 1,000 times 
greater affinity for TM (Kd = 1 nM) compared to 
fibrin (Kd = 1 μM), so it always prefers to bind to 
TM [13]. As the epitopes of binding of TM and 
fibrinogen, fibrin and PAR-1 overlap and the 
binding of thrombin to TM interferes with its 
procoagulant functions (2). Hirudin peptides and 
fibrinogen bind competitively to exosite I (15).  
Exosite II binds to the sulphated region (268-282) 
of Glycoprotein Ib (GpIb) and heparin with an 
almost equal affinity, but the thrombin prefers to 
bind to heparin because its concentration in the 
intact vascular endothelium is much greater 
than GpIb (13). This balance can be changed by 
vascular damage, endothelial dysfunction, 
inflammation or platelet activation. After 
coagulation, full clotting factor VIII activation 
requires cleavage at Arg372, a process involving 
thrombin exosite II. The sulphated region of GpIb 
binds to thrombin exosite II and is responsible for 
the inhibition of the Arg372-Ser373 bond 
cleavage and activation of FVIII (17). 
Another regulative site of thrombin is the Na+-
binding site. Na+ is octahedrally coordinated 
with the three water molecules and the three 
oxygen atoms of the carboxyl groups of 
thrombin [14, 18]. The effect is exclusively 
allosteric because the Na+-binding site is distant 
from the residues of the catalytic triad (10). The 
binding of Na+ ions dramatically changes the 
thrombin’s substrate specificity. The “fast” Na+-
bound form of thrombin actively cleaves 
fibrinogen, fibrin, clotting factors V and VIII and 
PAR. The “slow” Na+-free form has a high affinity 
for protein C. The transition from “slow” to “fast” 
thrombin results in the formation of the 
Arg187:Asp222 ion pair, the optimal orientation of 
Asp189 and Ser195 for substrate binding, and a 
significant shift of the side chain of Glu192 linked 
to the rearrangement of the network of water 
molecules that connect the bound Na+ to Ser195 
in the active site. Under physiological conditions, 
the concentration of Na+ is 140 mM. The Kd for 
Na+ binding to thrombin is 110 mM, which implies 
that nearly half of the thrombin molecules 
generated in vivo from prothrombin are in the 
Na+-free, “slow” form (18). 
It is suggested that the Na+-binding thrombin 
loop is directly involved in protein C interaction 
(2, 14). The binding of Na+ ions plays an important 
role in fibrinopeptide cleavage by thrombin, 
since the fibrinogen Aα-chain interacts more 
closely with the thrombin in the transition 
condition and, by stabilizing the Na+-bound form 
of thrombin, makes catalysis more effective (18). 
Hypernatremia (Na+ plasma concentration > 145 
mM) or hyponatremia (Na+ plasma 
concentration < 135 mM), which are the most 
common electrolyte disorders, are often 
associated with thrombosis or bleeding. Even 
under physiological conditions, the 
concentration of Na+ in the blood drops 
drastically close to platelet clot in vivo, proving 
the importance of Na+ in controlling the 
participation of thrombin and other enzymes 
(clotting factor Xa and protein C) in blood 
coagulation and thrombosis (18). 
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Thrombin action during coagulation 
Dissociation constants and second-order rate 
constants of thrombin are quite different for 
different partners (Table 1). The sequence and 
speed of cleaving of a substrate depend on the 
dynamic equilibrium between the concentration 
of free thrombin, thrombin bound to 
thrombomodulin, thrombin bound to platelets, 
thrombin in the antithrombin III-thrombin 
complex, etc. The thrombin affinity to SERPINs 
(serine protease inhibitors) is not very high, 
unlike the thrombin affinity to 
glycosaminoglycans (dissociation constants of 
110 nM and 90 nM for low and high molecular 
weight, respectively (19, 20)). This is why the only 
thrombin inhibitors – antithrombin III (ATIII) and 
heparin cofactor II (HC II) – use heparin and 
dermatan sulphate to achieve strong interaction 
with thrombin. Glycosaminoglycans accelerate 
thrombin inhibition by AT III or HC II 20,000- and 
70,000-fold, respectively. They decorate 
proteoglycans in vascular and extravascular 
spaces and bind to thrombin exosite II by ionic 
forces. Thrombin inhibition by SERPINs 
themselves in the absence of heparin is 
insignificant. At the same time, heparin presence 
advances thrombin inhibition and provides 
strong suppression of coagulation in resting 
vessels. 
Blood clotting cascade activation 
In the initial stage of the activation of blood 
coagulation, subnanomolar amounts of 
thrombin activate factors V and VIII. Both 
exosites are involved in thrombin recognition of 
these factors. This is how thrombin promotes the 
formation of the prothrombinase complex and 
thus enhances the process of its own formation 
through positive feedback regulation. As a 
result, a few thrombin molecules quickly raise 
thrombin production (13, 21). 
The picomolar concentration of thrombin also 
activates factor XI (22). The thrombin-GpIb 
complex can activate FXI on the surface of 
platelets, where thrombin and FXI are 
colocalized through separate GpIb interactions. 
Factor Va also was shown as a cofactor in the 
activation of FXI by thrombin both in a purified 
system and in blood plasma and requires 
phospholipid surfaces (23). But it is not clear 
whether GPIb and FVa work together or 
compete. 
Thrombin-cells interaction 
Membrane-bound enzyme complexes are 
critical for haemostasis (1). Complexes bound to 
the sub-endothelium or activated platelets 
provide blood coagulation activation, while 
complexes formed on the surface of the 
endothelium serve for coagulation inhibition. 
The density of the binding sites on different 
surfaces can direct haemostasis and change the 
status of the coagulation system. For example, 
about 1 % of fVII circulating in blood is normally 
activated, but it does not lead to coagulation or 
exceed the activation threshold because of the 
absence of a binding surface. 
While platelet-bound thrombin plays a 
procoagulant role, thrombin that is bound to 
endothelial cells provides anticoagulant action 
(24). 
Endothelium binding 
Thrombin recognizes three partners on the 
surface of the endothelium. Interaction of 
thrombin with heparan sulphate and 
thrombomodulin (TM) on the endothelium 
membrane is rapid, reversible and occurs with a 
high affinity (Table 1), whereas its binding to the 
membrane protein R-30 is slow, irreversible and 
occurs with a low affinity (25). This is the way to 
trigger thrombin activity from coagulant to 
anticoagulant (Figure 2). 
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Figure 2. Enzymatic activity points of free thrombin and membrane-bound enzyme 
Pl – platelet; APl – activated platelet; Fg – fibrinogen; Fn – fibrin; FDP – fibrin degradation products; TM – 
thrombomodulin; Hep – heparin; Thr – thrombin; PC – protein C; APC – activated protein C; EPCR – endothelial PC 
receptor; TAFI - thrombin-activated fibrinolysis inhibitor.© Korolova, 2021 
 
The most striking example of allosteric 
regulation of thrombin is the change in its 
enzymatic activity due to its binding to TM. 
Thrombin recognizes TM by the highly charged 
regions of exosite I and exosite II. Binding of the 
chondroitin sulphate moiety enhances the 
affinity of this interaction. The recognition event 
also involves conformational changes of the 
thrombin in the “slow” form, mediated by binding 
of the EGF-like domains 5-6 to exosite I (24).  
Protein C interacts weakly with thrombin due to 
the placement of polar amino acid residues of 
protein C near the apolar region of the “slit” of the 
active site of thrombin. TM interacts with 
thrombin exosite I by the protein part and with 
thrombin exosite II by the carbohydrate part. This 
way, it screens the “unfavourable” amino acid 
residues of protein C (26). As a result, TM 
significantly reduces the energy barrier and 
increases the rate of complex formation 
[thrombin + protein C] and thrombin activity, in 
relation to protein C, increases 10,000 times (2, 
27). In vivo, the reaction is enhanced 
approximately tenfold by the endothelial protein 
C receptor, which binds and localizes PC to the 
endothelium near TM (Figure 2) (28). 
Thrombomodulin is present in an amount of 
100,000 copies per endothelial cell. The 
concentration of free thrombomodulin in large 
vessels is approximately 0.1-0.2 nM. After 
interaction with thrombin, its local concentration 
increases up to 10 nM. It should be noted that in 
microvessels, the concentration of 
thrombomodulin reaches 500 nM. This is a prime 
example of how thrombin-binding sites density 
can direct haemostasis and provide a significant 
increase in protein C activity in the 
microcirculatory system (26). The thrombin-TM 
complex also activates the carboxypeptidase 
TAFI (thrombin-activated fibrinolysis inhibitor). 
Activated TAFI is able to cleave C-terminal 
lysine residues of fibrin, which typically form 
fibrinolytic protein binding sites. Thus, the 
activated TAFI protects the fibrin clot against 
lysis [29, 30]. This interaction is mediated by 
thrombomodulin-exosite I interaction, 
chondroitin sulphate-exosite II interaction and 
TAFI-active site interaction. Thrombin at high 
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concentrations binds to the low-affinity R-30 
protein on the endothelium surface (25). 
Thrombin has a low affinity to R-30 and this 
reaction is slow, but the binding of these proteins 
is covalent and irreversible. Thrombin R-30 
complex serves for thrombin uptake, 
internalization and degradation. 
Platelet binding 
Circulating thrombin levels under 100 pM 
maintain platelets in an inactivated state. 
Concentration increasing to 1 nM is enough for 
platelets activation. Thrombin partners on the 
platelet surface are PARs (protein activated 
receptors) and GPIb. Platelets provide 
negatively charged surfaces for coagulation 
factor assembly. Prothrombinase complex 
(factor Xa+Va assembled on a phospholipid in 
the presence of Ca2+) also works on the platelet 
surface, so thrombin formation is accelerated by 
acidic phospholipids and platelet activation is 
upregulated (Figure 2). At low thrombin 
concentrations, the platelet membrane 
glycoprotein Ib is involved in the interaction 
between platelets and thrombin. The binding of 
thrombin to GPIb is the responsibility of thrombin 
exosite II on one side and the N-terminal domain 
and negatively charged GPIb region on the 
other. Some experimental data (31) suggest that 
exosite I may also be another site for GPIb 
interaction. The high-affinity thrombin binding 
site is located in the α-subunit of the GPIb (268–
287 amino acid residues), but only a small 
fraction of the GPIb exposed on the platelet 
surface can bind thrombin and most of the 
receptors specifically bind only to the von 
Willebrand factor (32, 33). The thrombin-GpIb 
complex can enhance cleavage of GpV, 
resulting in hyperactivation of platelets. 
GPIb/IX/V signalling pathway mediates 
PI3k/Akt activation and protein phosphorylation 
(33, 34). It also mediates the increasing 
intracellular Ca2+ in thrombin-activated 
platelets. The result of thrombin-GPIb 
interaction is the stimulation of energy 
metabolism (glycolysis and oxidative 
phosphorylation) (34). 
GPIb can also be a cofactor in case of factor XI 
(FXI) and PAR activation by thrombin. Thrombin 
bound to platelet GpIb via exosite II is brought 
into proximity to PAR-1 and enhances its 
activation using exosite I to make contact (11, 13).  
Thrombin signalling in platelets depends 
principally on PARs. Thrombin binds PAR 
through exosite I and the active site. Thrombin 
cleavage of PAR is also exosite II-dependent 
due to the cofactor effect of GPIba, which 
accelerates the rate of reaction six- to sevenfold 
(11, 35, 36). Only PAR-1 and PAR-4 are exposed 
on human platelets and endothelium. PAR-1 is 
the primary thrombin receptor on platelets, 
requiring picomolar thrombin concentrations for 
effective activation, while PAR-4 cleavage is 
only relevant at high thrombin concentrations 
(PAR-4 contributes to thrombin-induced platelet 
aggregation at low thrombin concentrations in 
the range from ~ 0.4 nM to ~ 0.8 nM (37)). PAR-1 
mediates a rapid but transient platelet Ca2+ 
signalling response to thrombin, whereas PAR-4 
mediates a slower, sustained rise, producing the 
majority of calcium response (38). PAR-4 also 
plays a more important role in thrombin 
generation than PAR-1 (39). Both activation of 
PAR-4 and activation of PAR-1 induce granule 
release as a feedback mechanism to enhance 
and stabilize platelet aggregation, with PAR-1 
producing reversible aggregation and PAR-4 
producing irreversible aggregation (37). 
It is probable that the full response of human 
platelets requires the formation of a pair of 
receptors PAR-1 and PAR-4 [40]. PAR-4 does not 
have a sequence complementary to the 
thrombin exosites. Cleavage of PAR-4 platelets 
of humans requires a higher concentration of 
thrombin (~ 100 times) compared to the splitting 
of PAR-1. Activation of the PAR by thrombin 
begins with binding and cleavage (Arg41-Ser42) 
of the N-terminal region of the receptor, which 
results in the exposure of a new N-terminal 
region. This amino-terminus serves as a ligand 
for surfactants, intramolecularly binding to the 
extracellular portion of the receptor and 
inducing an intracellular signal (4, 41, 42). 
Thrombin activation is associated with G 
proteins by PAR activation. PARs signalling 
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mediates the activation of phospholipase C 
isoform β, PI3- and RhoA/Rho kinases (43-46). 
PARs also mediate increases in intracellular 
calcium in thrombin-activated platelets. This 
leads to changes in cytoskeletal actin and 
platelet surface exposure of fibrinogen-binding 
integrins IIbIIIa and activates further signalling 
and platelet aggregation. 
The prothrombinase complex converts 
prothrombin to thrombin by two pathways. Initial 
cleavage at Arg320 between the A and B chains 
generates meizothrombin, which is an active 
intermediate. The alternative initial cleavage at 
Arg271 cleaves off the Gla-domain and the two 
kringles and generates inactive prethrombin-2. 
Active thrombin is formed as a result of further 
cleavage of intermediates. Both ways take place 
in vivo (47–50).  
As previously shown, during the first minute of 
clotting system activation, the in vitro levels of 
both thrombin and meizothrombin are equal and 
can reach 0.8 μM (49). Moreover, 
meizothrombin can bind to the platelet 
membrane (51), so the local concentration of 
meizothrombin near the platelet surface may be 
significantly increased during the initial 
activation stage. We showed (52) that 
meizothrombin was able to enhance platelet 
aggregation induced by ADP, collagen or 
adrenalin. At the same time, being membrane-
bound, meizothrombin is not sensitive to 
antithrombin III in contradistinction to thrombin 
(51).  
Thrombin can also enhance platelet adhesion 
through cleavage of ADAMTS13, a proteinase 
responsible for the von Willebrand factor 
processing. Since the von Willebrand factor is a 
key platelet adhesion glycoprotein, by 
inactivating ADAMTS13, thrombin promotes 
platelet involvement at the site of injury (53). 
Fibrin clot formation 
The next step of thrombin activity is fibrinogen 
cleavage. Thrombin increasing to µM starts the 
conversion-of-fibrinogen-to-fibrin thrombin 
activity (Km for fibrinogen cleavage is 7.5 µM). 
Thrombin cleaves four fibrinogen bonds, 
cleaving two fibrinopeptides: fibrinopeptide A 
(fpA: 16-amino acid N-terminal peptide from the 
Aα chain) and fibrinopeptide B (fpB: 14-amino 
acid peptide from the Bβ chain) (54).  
During cleavage of fpA, thrombin binds directly 
to the Aα-chain of fibrinogen via exosite I and 
the active site. The release of fpA is sufficient for 
the polymerization of both fibrin and this form of 
monomeric fibrin desA, which spontaneously 
polymerizes to form protofibrils. When fpB is 
cleaved, fibrin desAB is formed and lateral 
association of protofibrils begins. However, the 
removal of fibrinopeptides B alone does not 
cause the polymerization of fibrin desB (2, 54, 55). 
It should be noted that the concentration of 
thrombin determines the features of the fibrin 
clot and its resistance to the action of the 
fibrinolytic system (56). 
Thrombin does not react with fibrin through 
exosite II. This allows the release of fibrin from 
the active site for clot formation and it is the 
reason why cleavage of fibrinopeptides is not 
the main thrombin activity. Thrombin interacts 
with the N-terminal E region of fibrin to release 
FpA and FpB, likely disrupting the interaction of 
the αC terminus with the E-region and exposing 
knobs A and B in the E-region, which interact 
with their specific binding pockets in the D-
regions of another fibrin molecule, leading to 
protofibril formation (16).  
By converting fibrinogen to fibrin, thrombin 
provides not only clot material, but also its own 
cofactor. Being bound to the fibrin E-region, 
thrombin uses fibrin as a cofactor for cleavage of 
factor XIII. Factor XIII is bound to the fibrin C-
terminal D-region. The fibrin monomers 
spontaneously polymerize and the E-region of 
one fibrin molecule is located closely to the D-
regions of two other fibrin molecules, moving 
factor XIII closer to thrombin. Thrombin activates 
clotting factor XIII by limited proteolysis of its 
subunit A. Factor XIIIa cross-links neighbouring 
fibrin molecules by covalent intermolecular 
bonds and cross-links inhibitors of fibrinolysis to 
fibrin (13, 57, 58).  
The newly generated polymer will provide the 
cofactor required for 80-fold accelerated factor 
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XIII activation (59). This ensures that factor XIIIa is 
generated when it is needed and where it is 
needed – on the fibrin clot surface. 
Interestingly, purified E-regions of fibrin interact 
with prothrombin, resulting in thrombin-like 
active site formation in the prothrombin 
molecule (60, 61). Thus, we can speculate that 
thrombin-E-region interaction provides not only 
a thrombin-based approach to factor XIII, but 
also provides changes in the active site of 
thrombin and accelerates factor XIII activation. 
Role of thrombin in pathology 
Historically, the procoagulant function of 
thrombin (the conversion of fibrinogen to fibrin) 
has been investigated earlier and more 
extensively. Based on the aforementioned facts, 
we can conclude that thrombin has a much 
wider range of action. Thrombin has a number of 
functions that can be activated depending on its 
concentration, localization and accessibility of 
partner molecules. So, the diversity of thrombin 
action provides regulation of haemostasis in 
general and its local concentration influences 
the thrombus microenvironment and 
architecture (62). Due to a great variety of protein 
partners, thrombin is a connector between 
plasma and platelet coagulation, between 
coagulation and anticoagulation, between 
haemostasis and the immune system and 
between endothelium pathology and 
coagulation disorders.  
Nowadays, thrombin remains a major target of 
antithrombotic and anticoagulant therapies in 
cardiovascular medicine. Heparins and direct 
thrombin inhibitors are currently used in the 
treatment of acute thrombotic complications, 
but a strategy that inhibits thrombin at the active 
site reduces not only procoagulant and 
prothrombotic functions, but also shuts down 
activity toward the anticoagulant protein C. 
Many researchers have been trying to convert 
thrombin into a potent and safe anticoagulant for 
in vivo applications. A new strategy aims at 
modulating thrombin function, rather than 
inhibiting it (10, 63). Some authors propose that 
mutant thrombin be used as a safe physiological 
anticoagulant (64) or apply a fusion protein, 
where thrombin and the TM domain are 
connected through a peptide linker (65). 
The shift of balance in pro- and anticoagulant 
action of thrombin becomes crucial for the 
development of haemostatic pathologies during 
inflammation and endothelial dysfunction. It 
should be emphasized that only the native intact 
endothelium provides the anticoagulant 
function of thrombin. So, any endothelium 
dysfunctions lead to triggering thrombin activity 
toward coagulation, which appears as 
thrombotic complications during some diseases. 
High levels of angiotensin II cause arterial 
hypertension by a complex vascular 
inflammatory pathway that requires leukocyte 
recruitment and reactive oxygen species 
production and is followed by vascular 
dysfunction. The resulting vascular inflammation 
and dysfunction are mediated by the activation 
of thrombin-driven FXI feedback, independent 
of factor XII. FXI receptor GPIb on platelets is 
required for this thrombin feedback activation 
[66]. Inhibition of this feedback loop with an 
antisense molecule against factor XI reduced 
both vascular pathology and hypertension. At 
the same time, there are doubts about the 
importance of feedback activation of factor XI 
(67). 
During bacterial and viral infections, there is an 
interplay between blood coagulation, immune 
cells and platelets to restrict the dissemination 
of pathogens within the body. Endothelial 
disturbance switches over coagulation and 
induces thrombotic complications, excessive 
inflammation and tissue damage. With regard to 
potential clinical significance, it is possible that 
interference with the PAR1 pathway by direct 
thrombin inhibitors or PAR1 inhibitors may 
increase the risk and severity of viral infection (6). 
Thrombin activity leads to endothelial cell 
activation in Klebsiella infection (bacterial 
pneumonia). Extrinsic pathway generated 
thrombin mediates fibrin polymerization and 
platelet‐neutrophil interactions essential for 
protective immune responses in at least 
Klebsiella pneumonia–derived sepsis [68]. TF is 
induced in the lung after an H1N1 IAV infection in 
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mice, which led to thrombin-induced 
hyperactivation of coagulation (6). At the same 
time, activated protein C seems to be involved in 
coagulation regulation during an H1N1 IAV 
infection. HIV infection is associated with 
increased [thrombin-antithrombin III]. Thrombin 
mediates the crosstalk between the coagulation 
system and the adaptive immune system at the 
sites of vascular injury through increased T-cell 
motility and production of proinflammatory 
cytokines during an HIV infection (6, 69). 
An infection that strongly affects coagulation is 
the coronavirus disease 2019 (COVID-19). It 
induces an immune response within the 
endothelium in blood vessels in several organs 
(70, 71). Studies of COVID-19 patients 
demonstrate the presence of fibrin thrombi 
within distended small vessels and capillaries 
and extensive extracellular fibrin deposition (72). 
Disseminated intravascular coagulation (DIC) 
has been reported to develop in 70 % of patients 
who succumb to the infection. D-dimer levels 
were increased far out of proportion to any 
abnormalities in the prothrombin time (PT/INR), 
activated partial thromboplastin time (APPT), 
fibrinogen level, or platelet count; these findings 
are uncharacteristic of DIC as currently 
understood.  
Hanny Al-Samkari  et al. stated that thrombosis 
is primarily associated with inflammatory 
markers, rather than coagulation parameters 
during a COVID-19 infection (73). Marco Ranucci 
et al. also demonstrated that coagulation is 
triggered by the release of IL-6 and other 
cytokines and the consequent release of tissue 
factor (74). 
Thrombin in laboratory diagnostics 
In recent times, the most widely used laboratory 
tests that indicate the imbalance of haemostasis 
have been the D-dimer test and 
thromboelastography. D-dimer is the fibrin 
degradation product appearing in the 
bloodstream as a result of stabilized fibrin 
cleavage by fibrinolysis. So, this parameter 
mainly indicates the existence of stabilized fibrin 
in the bloodstream and also the balance 
between coagulation and fibrinolysis (73, 75-77). 
The thromboelastography characterizes the 
clotting process in whole blood, providing 
information on clot formation and lysis overall 
(78). The thromboelastography testing has 
expanded to include managing extracorporeal 
membrane oxygenation therapy, assessing 
bleeding and assessing hypercoagulable 
conditions. In addition, thromboelastography 
platelet mapping has been utilized to monitor 
antiplatelet therapy (78).  
In particular, in patients with COVID-19, elevated 
circulating D-dimer levels are associated with 
mortality (79, 80). But the increasing of D-dimer 
levels occurs in both thrombosis and bleeding 
complications, so this parameter cannot be used 
as a thrombosis marker (81). Management of the 
thrombotic risk associated with COVID-19 is 
complicated by heparin treatment (82) and one 
of the approaches is  modification of the 
thrombin generation assays conditions by 
adding heparinase as a heparin neutralizing 
agent. 
Markers that directly indicate the appearance of 
active thrombin in the bloodstream are 
prothrombin fragment 1+2 (F1+2), prethrombin-1 
and soluble fibrin. Unfortunately, they are not 
incorporated in the routine laboratory practice. 
F1+2 is formed during the activation of 
prothrombin by prothrombinase complex (47), 
which is why it indicates prothrombinase activity. 
The appearance of this prothrombin derivative 
indicates the prothrombin activation to 
thrombin, so it is a direct method of thrombin 
detection. The nature of F1+2 makes it a more 
informative marker of procoagulant changes 
than clotting tests. Marco Ranucci et al. were 
able to show the direct appearance of thrombin 
by measuring F1+2 in the blood of patients with 
COVID-19 (74). Moreover, the F1+2 level was 
significantly reduced, whereas it increased in 
non-survivors. 
Another prothrombin derivative is Prethrombin-
1, which appears as a result of prothrombin 
autolysis by thrombin (9). It  is present in the 
bloodstream in case of intensive production of 
active non-inhibited thrombin, so it is a result of 
a strong activation of blood coagulation. A high 
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level of prethrombin-1 evidences the danger of 
intravascular clot formation (73, 83). 
On the other hand, thrombin activity is a useful 
predictor of the bleeding risk (73). Thrombin acts 
at the very end of the coagulation cascade and 
the decrease of its activity is associated with a 
high risk of bleeding. Several studies indicated 
the correlation between impaired thrombin 
generation and the severity of the disease (84). 
The tendency to bleeding was observed when 
thrombin generation fell below 20 % of the 
normal range (73). Similarly, a correlation 
between the generation of thrombin and the 
clinical bleeding phenotype in patients with 
deficiencies in blood coagulation factors FII, FV, 
FVII, FX and FIX has been observed.  
In the same way, as prethrombin-1 is a product 
of thrombin action on prothrombin, the soluble 
fibrin appears in the bloodstream as a result of 
the action of small amounts of thrombin on 
fibrinogen. Accumulating in small 
concentrations that are insufficient for clotting, 
fibrin desA forms oligomers and 
macromolecular complexes with fibrinogen, 
circulating in the bloodstream as non-cross-
linked soluble fibrin monomeric complexes. 
Being the direct result of thrombin action, its 
parameter clearly indicates the activation of 
blood coagulation even before intravascular 
clotting (76, 77, 85, 86).   
Thus, the level of thrombin as a diagnostic 
marker has not been neglected during infectious 
diseases, including COVID-19, and tests that can 
indicate it directly or indirectly are potentially 
useful in the prediction of haemostatic 




The presence of exosites, active site and Na+ site 
in the thrombin molecule allows thrombin to 
recognize a large number of substrates 
specifically. Thrombin substrates are important 
for platelet and fibrin clots formation, for 
activation and inhibition of the blood clotting 
cascade, for realization of the endothelial 
anticoagulant function and for the interaction of 
haemostasis and the immune system. Therefore, 
thrombin provides wide-scope and 
multidirectional action in haemostasis. On the 
other hand, imbalances of various links of 
haemostasis are reflected in thrombin activity 
and focus. 
This is the reason why a significant number of 
antithrombotic drugs are aimed at inhibiting 
thrombin activity. At the same time, inhibition of 
the general and not procoagulant thrombin 
activity is not the right approach from the point 
of view of the current understanding of 
haemostasis. 
Determination of thrombin activity, prothrombin 
concentration or concentration of prothrombin 
activation products are not traditional laboratory 
methods in hemostaseology, despite the fact 
that thrombin activity is one of the main factors 
of thrombotic disorders. In our opinion, 
characterization of the functional state of 
prothrombin/thrombin should be a required 
component of everyday laboratory practices. 
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